A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment
Conclusion:
Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.
Source: RETINA - Category: Opthalmology Tags: Review Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Education | Eyes | Opthalmology | Universities & Medical Training | Vasculitis | Vitamin A